CLBS
$1.57
Caladrius Bio
$.01
.64%
CLBS
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.26)
Revenue:  $0.00 Mil
Thursday
Feb 4
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CLBS reports earnings?
Beat
Meet
Miss

Where is CLBS's stock price going from here?
Up
Flat
Down
Stock chart of CLBS
Analysts
Summary of analysts' recommendations for CLBS
Score
Grade
Pivots
Resistance
$1.70
$1.64
$1.61

$1.55

Support
$1.52
$1.46
$1.43
Tweet
Growth
Description
Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.